Results 101 to 110 of about 1,128 (166)
Targeting of Specialized Metabolites Biosynthetic Enzymes to Membranes and Vesicles by Posttranslational Palmitoylation: A Mechanism of Non-Conventional Traffic and Secretion of Fungal Metabolites. [PDF]
Int J Mol SciMartín JF, Liras P.
europepmc +1 more source
Group I pharmaceuticals of IARC and associated cancer risks: systematic review and meta-analysis. [PDF]
Sci RepLim W +8 more
europepmc +1 more source
Drug repurposing screens reveal FDA approved drugs active against SARS-Cov-2
, 2020 Dittmar M +9 more
europepmc +1 more source
Pathogenicity of <i>Tolypocladium</i> spp. Against <i>Plutella xylostella</i>: Effects on Immune Enzyme Activities and Gene Expression Profile. [PDF]
InsectsCai N +6 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Southern Medical Journal, 1986
Cyclosporine is a fungal metabolite increasingly used as an immunosuppressive agent in organ transplantation. It provides immunosuppression primarily through reversible inhibition of T-lymphocytes, without myelotoxicity. Cyclosporine appears to inhibit primary activation of helper cells and to decrease the production of lymphokines by these cells ...
S E, Thomas, D S, Gordon
openaire +2 more sources
Cyclosporine is a fungal metabolite increasingly used as an immunosuppressive agent in organ transplantation. It provides immunosuppression primarily through reversible inhibition of T-lymphocytes, without myelotoxicity. Cyclosporine appears to inhibit primary activation of helper cells and to decrease the production of lymphokines by these cells ...
S E, Thomas, D S, Gordon
openaire +2 more sources
Drug Intelligence & Clinical Pharmacy, 1985
Cyclosporine is an immunosuppressant used to prevent the rejection of transplanted kidneys, hearts, and livers. Cyclosporine suppresses T-lymphocyte function without causing myelosuppression, and its pharmacokinetics are highly variable. Compared with conventional immunosuppressive drug therapy, both patient and graft survival improved in patients ...
R J, Ptachcinski +2 more
openaire +2 more sources
Cyclosporine is an immunosuppressant used to prevent the rejection of transplanted kidneys, hearts, and livers. Cyclosporine suppresses T-lymphocyte function without causing myelosuppression, and its pharmacokinetics are highly variable. Compared with conventional immunosuppressive drug therapy, both patient and graft survival improved in patients ...
R J, Ptachcinski +2 more
openaire +2 more sources
Journal of the American Academy of Dermatology, 1986
Cyclosporin A is a new immunosuppressive agent that selectively affects T helper cells without suppressing the bone marrow. Cyclosporin A has been used primarily to prevent rejection in organ transplantation and acute graft-versus-host disease. Studies suggest that it may be of benefit in psoriasis, pemphigus vulgaris, bullous pemphigoid, Behçet's ...
E H, Page, D M, Wexler, L C, Guenther
openaire +2 more sources
Cyclosporin A is a new immunosuppressive agent that selectively affects T helper cells without suppressing the bone marrow. Cyclosporin A has been used primarily to prevent rejection in organ transplantation and acute graft-versus-host disease. Studies suggest that it may be of benefit in psoriasis, pemphigus vulgaris, bullous pemphigoid, Behçet's ...
E H, Page, D M, Wexler, L C, Guenther
openaire +2 more sources
Journal of the American Academy of Dermatology, 1989
Cyclosporine is a potent immunosuppressive agent with no appreciable effect on the bone marrow and a selective inhibitory effect on helper T cells. Oral cyclosporine was first used to prevent organ rejection but also has been reported to be effective in other disorders. In cutaneous diseases that respond to oral cyclosporine helper T cells appear to be
A K, Gupta +7 more
openaire +2 more sources
Cyclosporine is a potent immunosuppressive agent with no appreciable effect on the bone marrow and a selective inhibitory effect on helper T cells. Oral cyclosporine was first used to prevent organ rejection but also has been reported to be effective in other disorders. In cutaneous diseases that respond to oral cyclosporine helper T cells appear to be
A K, Gupta +7 more
openaire +2 more sources
Transplantation Proceedings, 2004
The concentration at 2 hours after drug intake (C2) is proposed to optimise clinical outcomes in organ transplantation and for adjustment of the regimen of cyclosporine. A population based pharmacokinetic study was undertaken during the first 30 days post-liver transplantation.
M, Billing-Grima, P, Wolf
openaire +4 more sources
The concentration at 2 hours after drug intake (C2) is proposed to optimise clinical outcomes in organ transplantation and for adjustment of the regimen of cyclosporine. A population based pharmacokinetic study was undertaken during the first 30 days post-liver transplantation.
M, Billing-Grima, P, Wolf
openaire +4 more sources
Cyclosporine immunosuppression
American Journal of Health-System Pharmacy, 1984The chemistry, pharmacokinetics, mechanism of action, clinical efficacy in organ transplants, adverse effects, and dosage and administration of cyclosporine, a new immunosuppressant, are reviewed. Advice on counseling patients who take the drug is also included. Cyclosporine is a cyclic undecapeptide with a high molecular weight.
D M, Canafax, N L, Ascher
openaire +2 more sources